3,7,4'-Trihydroxy-5-methoxy-8-prenylflavanoneCAS# 204935-85-3 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 204935-85-3 | SDF | Download SDF |
| PubChem ID | 122169315 | Appearance | Powder |
| Formula | C21H22O6 | M.Wt | 370.4 |
| Type of Compound | Flavonoids | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | (2R,3R)-3,7-dihydroxy-2-(4-hydroxyphenyl)-5-methoxy-8-(3-methylbut-2-enyl)-2,3-dihydrochromen-4-one | ||
| SMILES | CC(=CCC1=C(C=C(C2=C1OC(C(C2=O)O)C3=CC=C(C=C3)O)OC)O)C | ||
| Standard InChIKey | CTUJEHJOZXGIIE-VQTJNVASSA-N | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
3,7,4'-Trihydroxy-5-methoxy-8-prenylflavanone Dilution Calculator
3,7,4'-Trihydroxy-5-methoxy-8-prenylflavanone Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.6998 mL | 13.4989 mL | 26.9978 mL | 53.9957 mL | 67.4946 mL |
| 5 mM | 0.54 mL | 2.6998 mL | 5.3996 mL | 10.7991 mL | 13.4989 mL |
| 10 mM | 0.27 mL | 1.3499 mL | 2.6998 mL | 5.3996 mL | 6.7495 mL |
| 50 mM | 0.054 mL | 0.27 mL | 0.54 mL | 1.0799 mL | 1.3499 mL |
| 100 mM | 0.027 mL | 0.135 mL | 0.27 mL | 0.54 mL | 0.6749 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Curzerenone
Catalog No.:BCN3009
CAS No.:20493-56-5
- Nardosinonediol
Catalog No.:BCN8118
CAS No.:20489-11-6
- Procumbide
Catalog No.:BCN3932
CAS No.:20486-27-5
- 8-O-Acetyltorilolone
Catalog No.:BCN7094
CAS No.:20482-21-7
- Fmoc-Lys(ivDde)-OH
Catalog No.:BCC3520
CAS No.:204777-78-6
- Olcegepant
Catalog No.:BCC1818
CAS No.:204697-65-4
- Epitaraxerol
Catalog No.:BCN4677
CAS No.:20460-33-7
- Talnetant hydrochloride
Catalog No.:BCC1982
CAS No.:204519-66-4
- BCH
Catalog No.:BCC7993
CAS No.:20448-79-7
- Fmoc-β-Homo-Phe-OH
Catalog No.:BCC2629
CAS No.:204384-69-0
- NS 2028
Catalog No.:BCC6212
CAS No.:204326-43-2
- RS 45041-190 hydrochloride
Catalog No.:BCC5682
CAS No.:204274-74-8
- Talatisamine
Catalog No.:BCN5403
CAS No.:20501-56-8
- Lansiumarin A
Catalog No.:BCN4894
CAS No.:205115-73-7
- Lansiumarin C
Catalog No.:BCN4895
CAS No.:205115-75-9
- (+)-Peusedanol
Catalog No.:BCC9119
CAS No.:20516-23-8
- 2'-MeCCPA
Catalog No.:BCC7311
CAS No.:205171-12-6
- Isonardoperoxide
Catalog No.:BCN7628
CAS No.:205248-65-3
- DL-TBOA
Catalog No.:BCC5735
CAS No.:205309-81-5
- Amifostine
Catalog No.:BCC5232
CAS No.:20537-88-6
- Pinocembrin 7-O-(3'-galloyl-4',6'-(S)-hexahydroxydiphenoyl)-beta-D-glucose
Catalog No.:BCN6769
CAS No.:205370-59-8
- BU 224 hydrochloride
Catalog No.:BCC6765
CAS No.:205437-64-5
- Taxezopidine G
Catalog No.:BCN6947
CAS No.:205440-22-8
- Paederoside
Catalog No.:BCN3437
CAS No.:20547-45-9
Identification of the Clinical Candidate (R)-(1-(4-Fluorophenyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-hexah ydro-1H-pyrazolo[3,4-g]isoquinolin-4a-yl)(4-(trifluoromethyl)pyridin-2-yl)methano ne (CORT125134): A Selective Glucocorticoid Receptor (GR) Antagonist.[Pubmed:28368581]
J Med Chem. 2017 Apr 27;60(8):3405-3421.
The nonselective glucocorticoid receptor (GR) antagonist mifepristone has been approved in the U.S. for the treatment of selected patients with Cushing's syndrome. While this drug is highly effective, lack of selectivity for GR leads to unwanted side effects in some patients. Optimization of the previously described fused azadecalin series of selective GR antagonists led to the identification of CORT125134, which is currently being evaluated in a phase 2 clinical study in patients with Cushing's syndrome.
Synthesis, Cytotoxic and Anti-proliferative Activity of Novel Thiophene, Thieno[2,3-b]pyridine and Pyran Derivatives Derived from 4,5,6,7-tetrahydrobenzo[b]thiophene Derivative.[Pubmed:28380235]
Acta Chim Slov. 2017 Mac;64(1):117-128.
Novel tetrahydrobenzo[b]thienopyrole derivatives are synthesized from 2-amino-3-cyano-4,5,6,7-tetrahydrobenzo[b]thiophene (1) through its reaction with alpha-chloroacetone to give the corresponding N-alkyl derivative 3. Compound 3 undergoes ready cyclization in sodium ethoxide solution to give the tetrahydrobenzo[b]thienopyrrole 4. The latter compound 4 is used as the key starting material for the synthesis of thiophene, thieno[2,3-b]pyridine and pyran derivatives. The cytotoxicity of the synthesized products towards the human cancer cell lines namely gastric cancer (NUGC), colon cancer (DLD-1), liver cancer (HA22T and HEPG-2), breast cancer (MCF-7), nasopharyngeal carcinoma (HONE-1) and normal fibroblast (WI-38) cell lines are measured. Compounds 4, 7a, 7b, 8a, 8b, 10c, 10d, 10f, 12a, 12b, 14b and 15b exhibit the optimal cytotoxic effect against cancer cell lines. Compounds 7b and 14b show the maximum inhibitory effect and these are much higher than the reference CHS-828 (pyridyl cyanoguanidine). On the other hand, the anti-proliferative evaluations of these compounds with high potency against the cancer cell lines L1210, Molt4/C8, CEM, K562, K562/4 and HCT116 show that compounds 7b and 8b give IC50's against Molt4/C8 and CEM cell lines higher than that of the reference, doxorubicin.
Synthesis, Structure, and Properties of Clathrate Si30.3(8) P15.7(8) Se7.930(3).[Pubmed:28378371]
Chemistry. 2017 Jul 18;23(40):9505-9516.
The new clathrate single crystal Si30.3(8) P15.7(8) Se7.930(3) was synthesized through a solid-state reaction, and it was characterized to have a unit cell parameter a=19.7614(1) A and belong to space group Fm3 . In this clathrate structure, a Se1-Si3 bond forms in place of the tetrakaidecahedron structure, and pental dodecahedral cages composed of Si and P atoms encapsulate Se2, Se3, and Se4 guest atoms. Similar structures are observed in partial Te- and Ge-substituted compounds. Theoretical calculations based on an ordered formula Si32 P14 Se7 showed a semiconducting electronic structure with a band gap of 0.711 eV. A photoelectric response was observed in this compound at room temperature. Across the whole temperature range, this material exhibited a weak temperature-dependent diamagnetic signal, and no phase transition or thermal anomaly was observed in heat capacity measurements.
Structure and Gene Cluster of the K93 Capsular Polysaccharide of Acinetobacter baumannii B11911 Containing 5-N-Acetyl-7-N-[(R)-3-hydroxybutanoyl]pseudaminic Acid.[Pubmed:28371606]
Biochemistry (Mosc). 2017 Apr;82(4):483-489.
Capsular polysaccharide (CPS) assigned to the K93 type was isolated from the bacterium Acinetobacter baumannii B11911 and studied by sugar analysis along with one- and two-dimensional (1)H and (13)C NMR spectroscopy. The CPS was found to contain a derivative of pseudaminic acid, and the structure of the branched tetrasaccharide repeating unit was established. Genes in the KL93 capsule biosynthesis locus were annotated and found to be consistent with the CPS structure established. The K93 CPS has the alpha-d-Galp-(1-->6)-beta-d-Galp-(1-->3)-d-GalpNAc trisaccharide fragment in common with the K14 CPS of Acinetobacter nosocomialis LUH 5541 and A. baumannii D46. It also shares the beta-d-Galp-(1-->3)-d-GalpNAc disaccharide fragment and the corresponding predicted Gal transferase Gtr5, as well as the initiating GalNAc-1-P transferase ItrA2, with a number of A. baumannii strains.
